Office of Scientific Program & Policy Analysis
The Office of Scientific Program and Policy Analysis (OSPPA) is the Institute's focal point for the coordination, analysis, and writing of a wide variety of scientific program reports, briefing materials, and other documents associated with the biomedical research programs of NIDDK and NIH. These documents present the scientific accomplishments and plans of NIDDK to public policy makers, including Congress; the scientific community; voluntary health organizations; and other lay audiences. OSPPA is the primary advisor to the NIDDK Director and other members of the Institute's senior staff on strategic planning and assessment approaches and on science policy issues. Office members provide direct staff support to the NIDDK Director with regard to researching scientific and policy issues relevant to NIDDK. Additionally, OSPPA serves as a liaison for dialogue with representatives of professional and patient advocacy groups and Congressional staff.
Reports and Planning Documents
Examples:
- Recent Advances and Emerging Opportunities
- NIDDK Strategic Plan for Research
- NIDDK Budget Request for FY 2024 (PDF, 1.78 MB)
- Pathways to Health for All: Health Disparities & Health Equity Research Recommendations & Opportunities
- 2020-2030 Strategic Plan for NIH Nutrition Research
- Special Statutory Funding Program for Type 1 Diabetes Research: Progress Report
- Advances and Emerging Opportunities in Diabetes Research: A Strategic Planning Report of the Diabetes Mellitus Interagency Coordinating Committee
For a more extensive listing, see: Strategic Plans & Reports and Budget & Legislative Information.
Office Staff
OSPPA currently includes an OSPPA leadership team (OSPPA Director and two Deputy Directors), Health Science Policy Analysts, and a Program Specialist. All of the Health Science Policy Analysts have doctoral degrees in fields of biomedical research, plus post-doctoral research experience, strong writing skills, and a dedication to communicating research advances and plans to public policy makers, professional and patient organizations, and other diverse scientific and lay audiences.